Does virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induce potent antitumor immunity against neuroblastoma?
We conclude that the ability of FusOn-H2 to induce tumor-specific cellular immunity expands the oncolytic repertoire of this virus and increases the likelihood that its use in patients would produce significant therapeutic benefits.
As the zona binding ability of fresh and unfertilized aged ICSI oocytes is similar, they can be used safely in zona assays.